Merck & Co Inc

NYSE:MRK  
79.96
-0.10 (-0.12%)
Products

FDA Approves Merck’s Keytruda For Triple‑Negative Breast Cancer

Published: 11/13/2020 21:19 GMT
Merck & Co Inc (MRK) - FDA Approves Merck’s Keytruda® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable Or Metastatic Triple‑negative Breast Cancer Whose Tumors Express Pd-l1 (cps ≥10).